Genentech and AC Immune's Semorinemab Flounders in P-II TAURIEL Study for Early Alzheimer's Disease
Shots:
- The P-II TAURIEL study involves assessing of semorinemab vs PBO in 457 patients with early AD across 97 sites
- Genentech divulges that the P-II TAURIEL study did not meet its co-1EPs of efficacy (reducing decline on CDR-SB) but meets its 1EPs of safety while the two 2EPs (ADAS-Cog13 & ADCS-ADL) was not met- results will be presented at the upcoming medical congress
- The second P-II LAURIET study of semorinemab in patients with moderate AD remains ongoing. Additionally- IND enabling studies are ongoing for first-in-class therapeutic candidates targeting TDP-43 and alpha-synuclein
Ref: PRNewswire | Image: Fortune
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com